Drug Type Small molecule drug |
Synonyms DFN-19 |
Target |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), ADRA2 antagonists(Adrenergic receptors alpha-2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | Phase 2 | US | 02 May 2019 |